<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) have a significant frequency of evolution into <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Approximately 30% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients show activating mutations of the N-<z:mp ids='MP_0011356'>RAS</z:mp> proto-oncogene, and these patients are at increased risk of leukaemic evolution </plain></SENT>
<SENT sid="2" pm="."><plain>Long-term survivors of aplastic <z:hpo ids='HP_0001903'>anaemia</z:hpo> (AA) and paroxysmal nocturnal haemoglobinurea (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e>) are also at significant risk of developing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>We have screened peripheral blood DNA from 42 AA patients and 15 PNH patients for the presence of N-<z:mp ids='MP_0011356'>RAS</z:mp> point mutations </plain></SENT>
<SENT sid="4" pm="."><plain>No mutations were detected in these samples, indicating that the mechanisms of evolution into <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> may be different from those in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>